

RECEITUÁRIO DE CONTROLE ESPECIAL

VIA DIGITAL
VALIDAR EM:
<https://assinaturadigital.it.gov.br>

IDENTIFICAÇÃO DO EMITENTE

NOME COMPLETO:
CRM: UF:
ENDEREÇO COMPLETO:

CIDADE: UF:
TELEFONE: DATA:



Logo do local de
atendimento
(imagem)

VINICIUS BORGES
DAS NEVES

Assinado de forma digital por
VINICIUS BORGES DAS NEVES
Dados: 2023.05.18 18:29:03 -03'00'

ASSINATURA MÉDICO(A)

NOME PACIENTE:

ENDEREÇO COMPLETO:

PRESCRIÇÃO:

IDENTIFICAÇÃO DO COMPRADOR

NOME COMPLETO:

RG:
ÓRGÃO EMISSOR:
ENDEREÇO COMPLETO:

CIDADE: UF:
TELEFONE:

IDENTIFICAÇÃO DO FORNECEDOR

NOME FARMACÊUTICO(A):

CRF: UF:
NOME FARMÁCIA:
ENDEREÇO:
CIDADE: UF:
CNPJ: TELEFONE:

ASSINATURA FARMACÊUTICO(A)

DADOS DO(S) PRODUTO(S) DISPENSADOS

NOME DO MEDICAMENTO: _____

LABORATÓRIO: _____

NÚMERO DO LOTE: _____ QUANTIDADE DE CAIXAS: _____

NÚMERO DE REGISTRO DA RECEITA NO LIVRO DE RECEITUÁRIO: _____
(QUANDO MEDICAMENTO MANIPULADO)

NOME DO MEDICAMENTO: _____

LABORATÓRIO: _____

NÚMERO DO LOTE: _____ QUANTIDADE DE CAIXAS: _____

NÚMERO DE REGISTRO DA RECEITA NO LIVRO DE RECEITUÁRIO: _____
(QUANDO MEDICAMENTO MANIPULADO)

NOME DO MEDICAMENTO: _____

LABORATÓRIO: _____

NÚMERO DO LOTE: _____ QUANTIDADE DE CAIXAS: _____

NÚMERO DE REGISTRO DA RECEITA NO LIVRO DE RECEITUÁRIO: _____
(QUANDO MEDICAMENTO MANIPULADO)

INFORMAÇÕES SOBRE INTERCAMBIALIDADE

O MEDICAMENTO _____
FOI SUBSTITUÍDO PELO GENÉRICO _____,
DE ACORDO COM A LEI 9787/99.

O MEDICAMENTO _____
FOI SUBSTITUÍDO PELO GENÉRICO _____,
DE ACORDO COM A LEI 9787/99.

O MEDICAMENTO _____
FOI SUBSTITUÍDO PELO GENÉRICO _____,
DE ACORDO COM A LEI 9787/99.

PARA DISPENSAÇÃO MANUAL

DATA: _____

ASSINATURA DO COMPRADOR: _____

ASSINATURA DO FARMACÊUTICO: _____

RELATÓRIO MÉDICO

VIA DIGITAL
VALIDAR EM:
<https://assinaturadigital.it.gov.br>

PACIENTE:

RELATÓRIO:

NOME DO(A) MÉDICO(A): CRM: UF:
LOCAL DE ATENDIMENTO: CNES:
ENDEREÇO: BAIRRO:
CIDADE: UF: TELEFONE:
DATA DE EMISSÃO:

ASSINATURA MÉDICO(A)

DOR CRÔNICA

1. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain*. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13. PMID: 24420962.
2. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain*. 2019 Apr;160(4):860-869. doi: 10.1097/j.pain.0000000000001464. PMID: 30585986; PMCID: PMC6430597.
3. Philpott HT, O'Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. *Pain*. 2017 Dec;158(12):2442-2451. doi: 10.1097/j.pain.0000000000001052. PMID: 28885454; PMCID: PMC5690292.
4. Häuser W, Fitzcharles MA, Radbruch L, Petzke F. Cannabinoids in Pain Management and Palliative Medicine. *Dtsch Arztebl Int*. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627. PMID: 29017688; PMCID: PMC5645627.
5. Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L. Cannabinoids suppress inflammatory and neuropathic pain by targeting $\alpha 3$ glycine receptors. *J Exp Med*. 2012 Jun 4;209(6):1121-34. doi: 10.1084/jem.20120242. Epub 2012 May 14. PMID: 22585736; PMCID: PMC3371734.
6. Casey SL, Atwal N, Vaughan CW. Cannabis constituent synergy in a mouse neuropathic pain model. *Pain*. 2017 Dec;158(12):2452-2460. doi: 10.1097/j.pain.0000000000001051. PMID: 28885457.
7. Kim PS, Fishman MA. Cannabis for Pain and Headaches: Primer. *Curr Pain Headache Rep*. 2017 Apr;21(4):19. doi: 10.1007/s11916-017-0619-7. PMID: 28281107.
8. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. PMID: 29513392; PMCID: PMC6494210.
9. Cuñetti L, Manzo L, Peyraube R, Arnaiz J, Curi L, Orihuela S. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. *Transplant Proc*. 2018 Mar;50(2):461-464. doi: 10.1016/j.transproceed.2017.12.042. PMID: 29579828.
10. Aviram J, Samuelli-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Pain Physician*. 2017 Sep;20(6):E755-E796. PMID: 28934780.
11. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. *Pain*. 2004 Dec;112(3):299-306. doi: 10.1016/j.pain.2004.09.013. PMID: 15561385.
12. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. *Postgrad Med*. 2020 Jan;132(1):56-61. doi: 10.1080/00325481.2019.1685298. Epub 2019 Nov 12. PMID: 31711352.
13. Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. *J Pain*. 2015 Dec;16(12):1221-1232. doi: 10.1016/j.jpain.2015.07.009. Epub 2015 Sep 9. PMID: 26362106; PMCID: PMC4666747.
14. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain*. 2013 Feb;14(2):136-48. doi: 10.1016/j.jpain.2012.10.009. Epub 2012 Dec 11. PMID: 23237736; PMCID: PMC3566631.
15. Banerjee S, McCormack S. Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul 24. PMID: 31532599.
16. Makary P, Parmar JR, Mims N, Khanfar NM, Freeman RA. Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain. *J Pain Palliat Care Pharmacother*. 2018 Dec;32(4):216-225. doi: 10.1080/15360288.2019.1598531. Epub 2019 May 9. PMID: 31070496.
17. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *Eur J Intern Med*. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4. PMID: 29307505.
18. Bar-Sela G, Zalman D, Semenysty V, Ballan E. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. *Integr Cancer Ther*. 2019 Jan-Dec;18:1534735419881498. doi: 10.1177/1534735419881498. PMID: 31595793; PMCID: PMC6785913.
19. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. *Rambam Maimonides Med J*. 2013 Oct 29;4(4):e0022. doi: 10.5041/RMMJ.10129. PMID: 24228165; PMCID: PMC3820295.

FIBROMIALGIA

1. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain*. 2019 Apr;160(4):860-869. doi: 10.1097/j.pain.0000000000001464. PMID: 30585986; PMCID: PMC6430597.
2. Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. *Arch Oral Biol*. 2019 Aug;104:33-39. doi: 10.1016/j.archoralbio.2019.05.028. Epub 2019 May 28. PMID: 31158702.
3. Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. *Cochrane Database Syst Rev*. 2016 Jul 18;7(7):CD011694. doi: 10.1002/14651858.CD011694.pub2. PMID: 27428009; PMCID: PMC6457965.

4. Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. *PLoS One*. 2011 Apr 21;6(4):e18440. doi: 10.1371/journal.pone.0018440. PMID: 21533029; PMCID: PMC3080871.
5. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. *Cannabis Cannabinoid Res*. 2016 Jul 1;1(1):154-165. doi: 10.1089/can.2016.0009. PMID: 28861491; PMCID: PMC5576607.
6. Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. *Clin Exp Rheumatol*. 2019 Jan-Feb;37 Suppl 116(1):13-20. Epub 2018 Oct 30. PMID: 30418116.
7. Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. *Schmerz*. 2016 Feb;30(1):47-61. doi: 10.1007/s00482-015-0084-3. PMID: 26767993.
8. Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, Marotto D, Ceribelli A, Ablin JN, Hauser W. Medical cannabis and cannabinoids in rheumatology: where are we now? *Expert Rev Clin Immunol*. 2019 Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997. PMID: 31512536.
9. Habib G, Artul S. Medical Cannabis for the Treatment of Fibromyalgia. *J Clin Rheumatol*. 2018 Aug;24(5):255-258. doi: 10.1097/RHU.0000000000000702. PMID: 29461346.
10. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J Pain*. 2008 Feb;9(2):164-73. doi: 10.1016/j.jpain.2007.09.002. Epub 2007 Nov 5. PMID: 17974490.
11. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and Efficacy of Medical Cannabis in Fibromyalgia. *J Clin Med*. 2019 Jun 5;8(6):807. doi: 10.3390/jcm8060807. PMID: 31195754; PMCID: PMC6616435.
12. Habib G, Avisar I. The Consumption of Cannabis by Fibromyalgia Patients in Israel. *Pain Res Treat*. 2018 Jul 22;2018:7829427. doi: 10.1155/2018/7829427. PMID: 30140459; PMCID: PMC6081591.